amotosalen has been researched along with Hemorrhage in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doree, C; Estcourt, LJ; Hopewell, S; Malouf, R; Murphy, MF; Stanworth, SJ; Trivella, M | 1 |
| Cauet, A; Martinaud, C; Sailliol, A | 1 |
| Brunskill, SJ; Butler, C; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, S; Trivella, M | 1 |
| Cid, J; Lozano, M | 1 |
| Benjamin, RJ; Carter, KL; Corash, L | 1 |
| Chaudhary, HT | 1 |
| Brand, A; de Greef, GE; Huijgens, PC; Kerkhoffs, JL; Luten, M; Novotny, VM; Schipperus, MR; Te Boekhorst, PA; van Pampus, LC; van Putten, WL; van Rhenen, DJ; Zwaginga, JJ | 1 |
| Hitzler, W; Vamvakas, EC | 1 |
| Buchholz, D; Cazenave, JP; Conlan, M; Corash, L; Davis, K; de Greef, G; Flament, J; Gulliksson, H; Kappers-Klunne, M; Klüter, H; Laforet, M; Lin, L; Lioure, B; Ljungman, P; Marblie, S; Mayaudon, V; Metzel, P; Pamphilon, D; van Rhenen, D; Vermeij, H | 1 |
| Benjamin, RJ; Buchholz, DH; Cable, R; Conlan, MG; Corash, L; Coutre, S; Davis, K; Fridey, JL; Goodnough, LT; Howard, F; Koutsoukos, A; Lin, JS; Lin, L; Lopez-Plaza, I; McCullough, J; Metzel, P; Murphy, S; Pineda, A; Raife, T; Slichter, SJ; Snyder, E; Stadtmauer, EA; Strauss, RG; Vesole, DH | 1 |
| Beris, P; Cazenave, JP; Conlan, MG; Flament, J; Hastka, J; Janetzko, K; Kientz, D; Klüter, H; Lin, JS; Lin, L; Lioure, B; Marblie, S; Mayaudon, V; Michel, M | 1 |
| Conlan, MG; Corash, L; Lin, JS; Lopez-Plaza, I; McCullough, J; Slichter, SJ; Snyder, E; Strauss, RG | 1 |
| Cable, R; Conlan, MG; Corash, L; Lin, JS; McCullough, J; Murphy, S; Slichter, SJ; Snyder, E; Strauss, RG | 1 |
| Sandler, SG | 1 |
| Buchholz, DH; Conlan, MG; Corash, L; Davis, K; Raife, TJ; Rheinschmidt, M; Slichter, SJ | 1 |
4 review(s) available for amotosalen and Hemorrhage
| Article | Year |
|---|---|
Pathogen-reduced platelets for the prevention of bleeding.
Topics: Adult; Antisepsis; Blood Platelets; Child; Disease Transmission, Infectious; Furocoumarins; Hemorrhage; Humans; Photosensitizing Agents; Platelet Transfusion; Randomized Controlled Trials as Topic; Riboflavin; Thrombocytopenia; Ultraviolet Rays | 2017 |
[Therapeutic plasmas available worldwide].
Topics: Blood Component Transfusion; Blood Donors; Blood Preservation; Blood Safety; Commerce; Detergents; Disasters; France; Freeze Drying; Furocoumarins; Global Health; Health Services Needs and Demand; Hemorrhage; Humans; Leukocyte Reduction Procedures; Methylene Blue; Microbial Viability; Photosensitizing Agents; Plasma; Riboflavin; Solvents; Ultraviolet Rays; Warfare; World Health Organization | 2013 |
Pathogen-reduced platelets for the prevention of bleeding.
Topics: Antisepsis; Blood Platelets; Furocoumarins; Hemorrhage; Humans; Photosensitizing Agents; Platelet Transfusion; Randomized Controlled Trials as Topic; Riboflavin; Ultraviolet Rays | 2013 |
Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
Topics: Bacteremia; Blood Platelets; Blood Safety; Blood-Borne Pathogens; Furocoumarins; Hemorrhage; Humans; Meta-Analysis as Topic; Microbial Viability; Multicenter Studies as Topic; Photochemistry; Photosensitizing Agents; Platelet Activation; Platelet Transfusion; Plateletpheresis; Randomized Controlled Trials as Topic; Ultraviolet Rays; Viremia | 2013 |
8 trial(s) available for amotosalen and Hemorrhage
| Article | Year |
|---|---|
Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Topics: Adult; Aged; Bacterial Infections; Blood Platelets; Blood Preservation; Female; Furocoumarins; Hemorrhage; Humans; Leukocyte Reduction Procedures; Male; Middle Aged; Plasma; Platelet Transfusion; Thrombocytopenia; Treatment Outcome; Ultraviolet Rays; Virus Diseases | 2010 |
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
Topics: Adult; Bacterial Infections; Blood Group Incompatibility; Blood Preservation; Double-Blind Method; Erythrocyte Transfusion; Female; Furocoumarins; Hemorrhage; Hemostasis; Humans; Male; Middle Aged; Photochemistry; Photosensitizing Agents; Platelet Count; Platelet Transfusion; Specimen Handling; Thrombocytopenia; Time Factors; Ultraviolet Rays; Virus Diseases | 2003 |
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Blood-Borne Pathogens; Child; Erythrocyte Transfusion; Female; Furocoumarins; Hemorrhage; Humans; Male; Middle Aged; Photochemistry; Platelet Transfusion; Prospective Studies; Thrombocytopenia | 2004 |
Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Topics: Adult; Aged; Antibodies; Bacterial Infections; Blood Component Removal; Erythrocyte Transfusion; Female; Furocoumarins; Hemorrhage; Humans; Male; Middle Aged; Photochemistry; Platelet Count; Platelet Transfusion; Thrombocytopenia; Ultraviolet Rays | 2005 |
Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Topics: Adult; Bacteria; Bacterial Infections; Blood Banking; Blood Banks; Cause of Death; Female; Furocoumarins; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Transfusion; Plateletpheresis; Safety; Skin Diseases; Thrombocytopenia; Thrombosis; Ultraviolet Rays | 2005 |
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Topics: Adult; Female; Furocoumarins; Hemorrhage; Humans; Male; Middle Aged; Platelet Transfusion; Thrombocytopenia; Ultraviolet Therapy | 2006 |
Treating thrombocytopenia with pathogen-reduced platelets.
Topics: Blood Platelets; Furocoumarins; Hemorrhage; Humans; Microbial Viability; Platelet Count; Platelet Transfusion; Plateletpheresis; Thrombocytopenia; Ultraviolet Rays | 2006 |
Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Topics: Adolescent; Adult; Bleeding Time; Blood Platelets; Bone Marrow Transplantation; Furocoumarins; Hematologic Neoplasms; Hemorrhage; Hemostasis; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Photosensitizing Agents; Platelet Transfusion; Plateletpheresis; Thrombocytopenia; Time Factors; Ultraviolet Rays | 2006 |
3 other study(ies) available for amotosalen and Hemorrhage
| Article | Year |
|---|---|
Amotosalen and ultraviolet-A treated platelets and plasma are safe and efficacious in active hemorrhage.
Topics: Blood Platelets; Furocoumarins; Hemorrhage; Humans; Plasma; Ultraviolet Rays | 2016 |
In-Silico Analysis of Amotosalen Hydrochloride Binding to CD-61 of Platelets.
Topics: Bleeding Time; Blood Platelets; Computer Simulation; Furocoumarins; Hemorrhage; Humans; Photosensitizing Agents; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2016 |
Platelet microRNA profiles and the effect of pathogen reduction on platelet function.
Topics: Blood Platelets; Blood-Borne Pathogens; Furocoumarins; Gamma Rays; Hemorrhage; Humans; Intercalating Agents; Meta-Analysis as Topic; MicroRNAs; Models, Biological; Multicenter Studies as Topic; Platelet Activation; Platelet Count; Platelet Transfusion; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Single-Blind Method; Ultraviolet Rays | 2011 |